Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$204.07
▼ $12.51 (-5.8%)
Market data updated: 09/16 04:16 AM
Fundamentals updated: 09/16/2026
News analyzed: 09/16/2026
Market Cap
$10.69B
Day Range
$203.78 - $215.02
52-Week Range
$113.85 - $260.19
Beta
—
Next Earnings
02.11.2026
AXSM is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+74.8% (1Y)
Strengths: 10/31 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 65.5%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$45.44 vs. price $204.07 (-122.3%)
Fair Value
Signal tension
Growth scores strong (82/100), but fair-value analysis scores this stock as relatively expensive (38/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
48
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
82
Quality
58
Value
38
Momentum
36
Risk
50
Sentiment
68
Fundamental
29
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Axsome Therapeutics has centered on its clinical advancements and investor activity. The company is prominently featured for initiating the **SUMMIT Phase III trial of AXS-05**, a potential smoking cessation treatment, marking a key milestone in its CNS-focused pipeline. Analysts, including HC Wainwright, have maintained a **bullish outlook**, reiterating a "Buy" rating with a $290 price target. Additionally, there was an **insider share sale** and speculation about **Auvelity’s revenue potential** in treating Alzheimer’s agitation post-launch. The focus remains on drug development and market positioning.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Axsome Therapeutics, Inc.. News trend score: 68. Reason: 5 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
10
🎯 Conviction (vs. Emotion)
44
Psychology
59
Fundamentals
29
Technical
36
Valuation
38
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
-19%
Market Narrative
50
Fundamental Reality
44
Narrative Gap
+6
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
👥 What the crowd believes
"Axsome Begins Phase III Study on AXS-05 for Smoking Cessation (Zacks)"
"HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 price target (Benzinga)"
"Auvelity Could Drive Revenue Beats After Launch in Alzheimer's Agitation (MT Newswires)"
"Axsome Therapeutics Stock Is Up 16% Year to Date (Motley Fool)"
📈 3D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 84/100
🔴 Weakest match
Benjamin Graham — 11/100
🗣️ Why do they disagree?
This stock splits methodologies into two starkly contrasting camps: Lynch, Mackay, and Fisher’s growth-oriented approaches see it as a promising opportunity, with Lynch calling it a ‘growth candidate’ and Fisher acknowledging its solid fundamentals—even if not exceptional. Meanwhile, Nelson and Marks (cycle-focused) lean cautiously optimistic, viewing it as undervalued relative to its cycle position, though Marks’ broader outlook remains guarded. The divide sharpens when comparing these to the more risk-averse or market-skeptical frameworks: Graham’s defensive criteria and Livermore’s trend-following rule outright reject it, while Loeb and Veblen flag red flags like speculative overreach or unsustainable growth. Even the efficient-market camp dismisses it as unconvincing compared to passive indexing, illustrating a tension between active stock-picking and broader market neutrality. The middle ground—where Smith, Marks (general), and Housel sit—suggests it’s holdable but lacks the clarity or safety to be a core holding.
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 84
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 83
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 79
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 72
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 69
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 61
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 56
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 50
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 48
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 45
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 41
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 34
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 33
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 31
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 11
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Based on the last 277 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 7 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-26.1%
Net Margin
-28.7%
EBITDA Margin
-26.1%
ROE
-207.5%
ROA
-26.6%
ROIC
—
EPS
-$3.68
Cash
$322.93M
Total Debt
$187.75M
Current Ratio
1.55
Debt/Equity
2.13
How is Fair Value calculated? →
Current Price
$204.07
Estimated Fair Value (DCF)
-$45.44
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-122.3%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $-117.36M | $-107.67M |
| 2 | 19.4% | $-140.09M | $-117.91M |
| 3 | 13.8% | $-159.36M | $-123.05M |
| 4 | 8.1% | $-172.30M | $-122.06M |
| 5 | 2.5% | $-176.61M | $-114.79M |
Base FCF (last actual year)
$-93.89M
Terminal Value
$-2.79B
Present Value of Terminal Value
$-1.81B
Enterprise Value
$-2.40B
Net Debt
$-135.19M
Equity Value
$-2.26B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$1.77
Tangible Book Value per Share (Tangible NAV)
$0.72
Sentiment based on basic keywords (not AI) — 5 positive, 13 neutral, 2 negative out of the last 20 articles.
SeekingAlpha · 14.9.2026
Yahoo · 11.9.2026
Yahoo · 11.9.2026
SeekingAlpha · 10.9.2026
Yahoo · 10.9.2026
Motley Fool · 10.9.2026
SeekingAlpha · 9.9.2026
Yahoo · 9.9.2026
Zacks · 9.9.2026
MT Newswires · 4.9.2026
Yahoo · 2.9.2026
GlobeNewswire · 2.9.2026
Yahoo · 1.9.2026
Zacks · 1.9.2026
MT Newswires · 1.9.2026
MT Newswires · 31.8.2026
Benzinga · 31.8.2026
MT Newswires · 31.8.2026
Yahoo · 31.8.2026
GlobeNewswire · 31.8.2026
Axsome Therapeutics, Inc. (AXSM) currently has a StockIQ AI score of 48/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
AXSM currently scores 48/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, AXSM's estimated fair value is -$45.44, which is 122.3% below the current price of $204.07. This is one valuation model among several signals in the fair-value category, not a price target.
AXSM's technical score is 36/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 65.5%; Earnings per share (EPS) growth: 38.6%; Free cash flow growth: 27.0%.
Based on the real signals StockIQ computed: Estimated fair value: -$45.44 vs. price $204.07 (-122.3%); Operating margin: -26.1% (negative); Net margin: -28.7% (negative).
StockIQ has no recorded dividend payment history for AXSM.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 11 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Jacobson Mark L. | Open Market Sale | 3.9.2026 | 10,000 | -10,000 | $208.65 |
| Jacobson Mark L. | Exercise of Derivative Securities | 3.9.2026 | 10,000 | +10,000 | $12.95 |
| Jacobson Mark L. | Exercise of Derivative Securities | 3.9.2026 | 10,000 | -10,000 | — |
| TABUTEAU HERRIOT | Open Market Sale | 6.8.2026 | 4,660 | -4,660 | $213.95 |
| TABUTEAU HERRIOT | Exercise of Derivative Securities | 6.8.2026 | 4,660 | -4,660 | — |
| TABUTEAU HERRIOT | Exercise of Derivative Securities | 6.8.2026 | 4,660 | +4,660 | $4.95 |
| TABUTEAU HERRIOT | Exercise of Derivative Securities | 6.8.2026 | 11,889 | +4,660 | $4.95 |
| TABUTEAU HERRIOT | Open Market Sale | 6.8.2026 | 7,229 | -4,660 | $213.95 |
| TABUTEAU HERRIOT | Exercise of Derivative Securities | 6.8.2026 | 0 | -4,660 | — |
| TABUTEAU HERRIOT | Exercise of Derivative Securities | 5.8.2026 | 45,004 | -45,004 | — |
| TABUTEAU HERRIOT | Exercise of Derivative Securities | 5.8.2026 | 45,004 | +45,004 | $4.95 |
| TABUTEAU HERRIOT | Open Market Sale | 5.8.2026 | 45,004 | -45,004 | $212.01 |
| TABUTEAU HERRIOT | Exercise of Derivative Securities | 5.8.2026 | 4,660 | -45,004 | — |
| TABUTEAU HERRIOT | Exercise of Derivative Securities | 5.8.2026 | 52,233 | +45,004 | $4.95 |
| TABUTEAU HERRIOT | Open Market Sale | 5.8.2026 | 7,229 | -45,004 | $212.01 |
| TABUTEAU HERRIOT | Exercise of Derivative Securities | 1.7.2026 | 49,666 | -49,666 | — |
| TABUTEAU HERRIOT | Exercise of Derivative Securities | 1.7.2026 | 49,666 | +49,666 | $4.95 |
| TABUTEAU HERRIOT | Open Market Sale | 1.7.2026 | 49,666 | -49,666 | $240.25 |
| TABUTEAU HERRIOT | Exercise of Derivative Securities | 1.7.2026 | 56,895 | +49,666 | $4.95 |
| TABUTEAU HERRIOT | Open Market Sale | 1.7.2026 | 7,229 | -49,666 | $240.25 |
| TABUTEAU HERRIOT | Exercise of Derivative Securities | 1.7.2026 | 49,664 | -49,666 | — |
| JEFFS ROGER | Open Market Sale | 11.6.2026 | 286 | -286 | $249.12 |
| JEFFS ROGER | Open Market Sale | 11.6.2026 | 58,367 | -286 | $249.12 |
| Mahony Susan | Open Market Sale | 10.6.2026 | 300 | -300 | $246.18 |
| Coleman Mark | Open Market Sale | 10.6.2026 | 643 | -643 | $249.00 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
3,080,218 shares short as of 2026-08-31 · vs. 3,407,383 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
53.5% of trading volume this week was short selling, vs. 68.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology